TABLE 1.
Clinical characteristics of COVID-19 patients in the cohort
| Characteristic | Value (N = 36) |
|---|---|
| Female (n [%]) | 28 (77.8) |
| Age (yrs) (median [IQR]) | 33.5 (27.7–45.6) |
| Body mass index (kg/m2) (median [IQR]) | 25.0 (21.1–29.1) |
| Underlying disease (n [%]) | |
| Hypertension | 5 (13.9) |
| Hyperlipidemia | 4 (11.1) |
| Diabetes mellitus | 3 (8.3) |
| Malignancy | 1 (2.8) |
| Duration of symptom before hospitalization (days) (median [IQR]) | 3 (2–4) |
| Complete 2-dose vaccination (n [%]) | 14 (38.9) |
| Inactivated vaccine | 13 (13.1) |
| Heterologous inactivated/ChAdOx1 nCoV-19 vaccination | 1 (2.8) |
| Symptom at the diagnosis (n [%]) | 35 (97.2) |
| Pneumonia (n [%]) | 10 (27.8) |
| Oxygen support (n [%]) | 3 (8.3) |
| Treatment (n [%]) | |
| Favipiravir | 19 (52.8) |
| Dexamethasone | 5 (13.9) |
| Tocilizumab | 1 (2.8) |
| Viral strain identified | |
| Wild type | 4 (11.1) |
| Alpha | 13 (36.1) |
| Delta | 18 (50.0) |